Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study

Sepsis Clinical Trial

— FAPIC-QE  

Official title:

Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04103203
• Other study ID #: 19.51/Infect.19.02
• Status: Completed
• Phase: N/A
• Start date: July 1, 2019
• Est. completion date: April 30, 2020

Study information

• Verified date: October 2020
• Source: Hasselt University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The performance and clinical impact of two diagnostic systems will be evaluated using whole blood samples that are collected in parallel with samples for blood culture. As the rapid diagnostic systems will have the largest impact on severely ill patients (in need of a fast diagnosis) with bacterial infection, the evaluation will be performed in patients suspected of bacteraemia. During the study the new systems will be used in parallel with routine blood cultures. In alternating periods of 1 month, the results of the diagnostic system will be communicated to treating physicians (intervention) or not revealed (control). Blood culture results will be reported throughout the complete study period. Patients with suspected sepsis at the Emergency Department (ED), the department of infectious diseases/nephrology, and the department of haemodialysis will be included. In routine care, two blood culture sets (2x2 bottles) per patient are collected. One extra blood sample (EDTA tube, 9 ml of blood) will be sampled for each routine set of blood cultures. In addition, the clinical data of the patients will be collected. The samples will be sent to the clinical laboratory where samples are tested with the new systems during regular working hours in batches of 8 samples per run (2-3 runs per day). On average, 10%-20% of the blood cultures drawn on the presumption of bacteraemia yield bacterial pathogens. Previous data show that 13% of patients yield positive blood cultures. Thus, in order to collect blood samples of 100 new episodes of bacteraemia approximately 1000 patients (2000 blood cultures + 1000 EDTA tubes) have to be collected for each system (2000 patients in total). The results of the systems will be used to evaluate the clinical utility of the system regarding time to antibiotic treatment change and bacteraemia management. The system will be used directly for the diagnosis of patients, resulting in a possible change of treatment strategy. However, routine blood culture practices will still be done during the whole study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1978
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Suspicion of sepsis

• The drawning of blood cultures

• Age >18 years

Exclusion Criteria:

• Children (<18 years)

• Patients who are not hospitalized and sent home after ED admission

• Duplicate blood cultures from the same bacteraemia episode (7days between positives with the same organism, or 24h for different organisms)

• Patients from who blood cultures are drawn on Friday evening (17h) or Saturday during intervention periods

Related Conditions & MeSH terms

• Bacteremia
• Sepsis
• Septic Shock

Intervention

Diagnostic Test:
• PathoRobot/ Patho-Doc Test result
Test results of the new diagnostics will be available to the treating physician.

Locations

Country	Name	City	State
Belgium	Jessa Hospital	Hasselt	Limburg

Sponsors (9)

Lead Sponsor	Collaborator
Hasselt University	AIT Austrian Institute of Technology GmbH, Axo Science, BEE Robotics, Claude Bernard University, Jessa Hospital, Molzym, School of Medicine, University of Zagreb, University of Warwick

Country where clinical trial is conducted

Belgium, 

References & Publications (3)

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18. — View Citation

Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289. Review. — View Citation

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median time from specimen collection/arrival in the laboratory until antibiotic regimen change	Time period between collection of blood cultures until the first change in antibiotic regimen	at study completion, 10 months
Secondary	Median time to appropriate, species-specific antibiotic therapy	Time period between collection of blood cultures until the first administration of species-specific antibiotic therapy	at study completion, 10 months
Secondary	In-hospital mortality	In-hospital mortality	at study completion, 10 months
Secondary	Time to organism identification	Time period between collection of blood cultures until the time to identification of a causative organism with the new diagnostics and with blood cultures	at study completion, 10 months
Secondary	Time to effective therapy	Time period between collection of blood cultures until the first administration of antibiotic therapy effective againts the causative organism	at study completion, 10 months
Secondary	Time to optimal therapy	Time period between collection of blood cultures until the first administration of antibiotic therapy that is optimal for patient recovery	at study completion, 10 months
Secondary	30-day all cause mortality	Number of patients with 30-day all cause mortality	at study completion, 10 months
Secondary	Length-of-stay	Length of hospital stay	at study completion, 10 months
Secondary	Length of ICU stay	Length of stay in an Intensive Care Unit	at study completion, 10 months
Secondary	Destination at Discharge	Destination after discharge (home, rehabilitation home, nursing home, ...)	at study completion, 10 months